Immunologic Research

, Volume 64, Issue 4, pp 831–840 | Cite as

Immunomodulatory effects of mesenchymal stromal cells-derived exosome

  • Wancheng Chen
  • Yukai Huang
  • Jiaochan Han
  • Lili Yu
  • Yanli Li
  • Ziyuan Lu
  • Hongbo Li
  • Zenghui Liu
  • Chenyan Shi
  • Fengqi Duan
  • Yang Xiao
Original Article

Abstract

The mechanisms underlying immunomodulatory ability of mesenchymal stromal cells (MSCs) remain unknown. Recently, studies suggested that the immunomodulatory activity of MSCs is largely mediated by paracrine factors. Among which, exosome is considered to play a major role in the communication between MSCs and target tissue. The aim of our study is to investigate the effect of MSCs-derived exosome on peripheral blood mononuclear cells (PBMCs), especially T cells. We find that the MSCs-derived exosome extracted from healthy donors’ bone marrow suppressed the secretion of pro-inflammatory factor TNF-α and IL-1β, but increased the concentration of anti-inflammatory factor TGF-β during in vitro culture. In addition, exosome may induce conversion of T helper type 1 (Th1) into T helper type 2 (Th2) cells and reduced potential of T cells to differentiate into interleukin 17-producing effector T cells (Th17). Moreover, the level of regulatory T cells (Treg) and cytotoxic T lymphocyte-associated protein 4 were also increased. These results suggested that MSC-derived exosome possesses the immunomodulatory properties. However, it showed no effects on the proliferation of PBMCs or CD3+ T cells, but increases the apoptosis of them. In addition, indoleamine 2, 3-dioxygenase (IDO) was previously shown to mediate the immunoregulation of MSCs, which was increased in PBMCs co-cultured with MSCs. In our study, IDO showed no significant changes in PBMCs exposed to MSCs-derived exosome. We conclude that exosome and MSCs might differ in their immune-modulating activities and mechanisms.

Keywords

Mesenchymal stem cells Exosome Immunomodulation Peripheral blood mononuclear cells 

References

  1. 1.
    Nold P, et al. Immunosuppressive capabilities of mesenchymal stromal cells are maintained under hypoxic growth conditions and after gamma irradiation. Cytotherapy. 2015;17(2):152–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Tobin LM, et al. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol. 2013;172(2):333–48.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wuchter P, et al. Standardization of good manufacturing practice–compliant production of bone marrow–derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy. 2015;17(2):128–39.CrossRefPubMedGoogle Scholar
  4. 4.
    Lee SM, Lee SC, Kim SJ. Contribution of human adipose tissue-derived stem cells and the secretome to the skin allograft survival in mice. J Surg Res. 2014;188(1):280–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Morigi M, Benigni A. Mesenchymal stem cells and kidney repair. Nephrol Dial Transplant. 2013;28(4):788–93.CrossRefPubMedGoogle Scholar
  6. 6.
    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Nauta AJ, et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol. 2006;177(4):2080–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Rakha A, Todeschini M, Casiraghi F. Assessment of anti-donor T cell proliferation and cytotoxic T lymphocyte-mediated lympholysis in living donor kidney transplant patients. Methods Mol Biol. 2014;1213:355–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Tabera S, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica. 2008;93(9):1301–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Swart J, et al. Mesenchymal stem cell therapy in proteoglycan induced arthritis. Ann Rheum Dis. 2015;74(4):769–77.CrossRefPubMedGoogle Scholar
  11. 11.
    Woodworth TG, Furst DE. Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy. Arthritis Res Ther. 2014;16(4):113.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wu Y, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res. 2014;12(1):132–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Chinnadurai R, et al. Mesenchymal stromal cells derived from Crohn’s patients deploy indoleamine 2, 3-dioxygenase-mediated immune suppression, independent of autophagy. Mol Ther. 2015;23(7):1248–61.CrossRefPubMedGoogle Scholar
  14. 14.
    de Mare-Bredemeijer EL, et al. Human graft-derived mesenchymal stromal cells potently suppress alloreactive T-cell responses. Stem Cells Dev. 2015;24(12):1436–47.CrossRefPubMedGoogle Scholar
  15. 15.
    Laranjeira P, et al. Effect of human bone marrow mesenchymal stromal cells on cytokine production by peripheral blood naive, memory, and effector T cells. Stem Cell Res Ther. 2015;6(1):3.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Najar M, et al. Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the t cell response: the importance of the IL-10/CD210 axis. Stem Cell Rev Rep. 2015;11(3):442–52.CrossRefGoogle Scholar
  17. 17.
    Akyurekli C, et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Reviews and Reports. 2014;11(1):150–60.CrossRefGoogle Scholar
  18. 18.
    Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195–208.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bruno S, Camussi G. Exploring mesenchymal stem cell-derived extracellular vesicles in acute kidney injury. In: Animal models for stem cell therapy. Springer; 2014. p. 139–45.Google Scholar
  20. 20.
    Gouveia de Andrade AV, et al. Extracellular vesicles secreted by bone marrow-and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 2015;24(11):1374–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Katsuda T, et al. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics. 2013;13(10–11):1637–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Kordelas L, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28(4):970.PubMedGoogle Scholar
  23. 23.
    Del Fattore A, et al. Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes. Cell Transplant. 2015;24(12):2615–27.CrossRefPubMedGoogle Scholar
  24. 24.
    Caby MP, et al. Exosomal-like vesicles are present in human blood plasma. Int Immunol. 2005;17(7):879–87.CrossRefPubMedGoogle Scholar
  25. 25.
    Hashemi SM, et al. Comparative immunomodulatory properties of adipose-derived mesenchymal stem cells conditioned media from BALB/c, C57BL/6, and DBA mouse strains. J Cell Biochem. 2013;114(4):955–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res. 2015;2015:394917.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Rosado MM, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015;24(1):93–103.CrossRefPubMedGoogle Scholar
  28. 28.
    Ryan J, et al. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149(2):353–63.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zhou Y, et al. Mesenchymal stromal cells augment CD4+ and CD8+ T-cell proliferation through a CCL2 pathway. Cytotherapy. 2013;15(10):1195–207.CrossRefPubMedGoogle Scholar
  30. 30.
    Dorronsoro A, et al. Human mesenchymal stromal cells modulate T-cell responses through TNF-alpha-mediated activation of NF-kappaB. Eur J Immunol. 2014;44(2):480–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Silva A, et al. Bone marrow-derived mesenchymal stem cells and their conditioned medium attenuate fibrosis in an irreversible model of unilateral ureteral obstruction. Cell Transplant.  2015;24(12):2657–66.CrossRefPubMedGoogle Scholar
  32. 32.
    Uchibori R, et al. Cancer gene therapy using mesenchymal stem cells. Int J Hematol. 2014;99(4):377–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res. 2015;2015:394917.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Conforti A, et al. Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem cells and development. 2014;23(21):2591–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lai RC, Yeo RW, Lim SK. Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015;40:82–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Tan CY, Lai RC, Wong W, Dan YY, Lim S-K, Ho HK. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014;5:76.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Collino F, et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One. 2010;5(7):e11803.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kilpinen L, et al. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. J Extracell Vesicles. 2013;2:21927.CrossRefGoogle Scholar
  39. 39.
    Mokarizadeh A, et al. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012;147(1):47–54.CrossRefPubMedGoogle Scholar
  40. 40.
    Takahashi T, et al. Immunologic self-tolerance maintained by CD25(+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303–10.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Sivanathan KN, et al. Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function. Stem Cells. 2015;33(9):2850–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Wancheng Chen
    • 1
    • 2
  • Yukai Huang
    • 1
  • Jiaochan Han
    • 1
  • Lili Yu
    • 1
  • Yanli Li
    • 1
  • Ziyuan Lu
    • 1
  • Hongbo Li
    • 1
    • 2
  • Zenghui Liu
    • 2
  • Chenyan Shi
    • 1
    • 2
  • Fengqi Duan
    • 1
    • 2
  • Yang Xiao
    • 1
    • 2
    • 3
  1. 1.Southern Medical UniversityGuangzhouChina
  2. 2.Department of HematologyGeneral Hospital of Guangzhou Military CommandGuangzhouChina
  3. 3.Department of HematologyThe Third Affiliated Hospital of Southern Medical University (Academy of Orthopedics-Guangdong Province)GuangzhouChina

Personalised recommendations